Koninklijke Philips NV ADR (PHG)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $29.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Koninklijke Philips NV ADR (PHG) Financials: Revenue, Profit and Cash Flow
Koninklijke Philips NV ADR reported revenue of EUR 17.83B for the fiscal year ended Dec 31, 2025, down 1.0% from the year before. That year, net income was EUR 895.00M with a net margin of 5.0%, operating cash flow was EUR 1.16B and free cash flow was EUR 893.00M. The quarter ended Sep 30, 2026 had revenue of EUR 4.37B and net income of EUR 26.84M.
Revenue and Margins
The operating margin was 8.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from EUR 24.52B, a compound annual decline of 3.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 17.83B | -1.0% | 45.2% | 8.0% | 5.0% |
| Dec 2024 | 18.02B | -0.8% | 43.1% | 2.9% | -3.9% |
| Dec 2023 | 18.17B | +1.9% | 41.0% | -0.6% | -2.6% |
| Dec 2022 | 17.83B | +3.9% | 40.4% | -8.6% | -9.0% |
| Dec 2021 | 17.16B | -0.9% | 41.8% | 3.2% | 19.3% |
| Dec 2020 | 17.31B | +1.0% | 45.7% | 7.3% | 6.9% |
| Dec 2019 | 17.15B | -5.4% | 46.4% | 8.0% | 6.8% |
| Dec 2018 | 18.12B | +1.9% | 47.2% | 9.5% | 6.0% |
| Dec 2017 | 17.78B | -27.5% | 46.0% | 8.5% | 9.3% |
| Dec 2016 | 24.52B | N/A | 43.3% | 7.7% | 5.9% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 85.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.83B | 18.02B | 18.17B | 17.83B | 17.16B | 17.31B | 17.15B | 18.12B | 17.78B | 24.52B |
| Cost of revenue | 9.78B | 10.25B | 10.72B | 10.63B | 9.99B | 9.40B | 9.20B | 9.57B | 9.60B | 13.90B |
| Gross profit | 8.06B | 7.77B | 7.45B | 7.19B | 7.17B | 7.91B | 7.95B | 8.55B | 8.18B | 10.61B |
| Research and development | 1.70B | 1.75B | 1.89B | 2.09B | 1.81B | 1.91B | 1.79B | 1.76B | 1.76B | 2.02B |
| Operating income | 1.42B | 529.00M | -115.00M | -1.53B | 553.00M | 1.26B | 1.37B | 1.72B | 1.52B | 1.88B |
| Net income | 895.00M | -702.00M | -466.00M | -1.61B | 3.32B | 1.19B | 1.17B | 1.09B | 1.66B | 1.45B |
| EBITDA | 2.64B | 1.85B | 1.04B | 115.00M | 2.00B | 3.15B | 3.06B | 2.79B | 2.65B | 2.35B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.37B | 4.36B | 3.90B | 5.10B | 4.30B | 4.34B | 4.10B | 5.04B | 4.38B | 4.46B | 4.14B | 5.06B |
| Gross profit | 2.03B | 2.15B | 1.77B | 2.29B | 1.91B | 2.01B | 1.85B | 1.96B | 2.01B | 1.99B | 1.81B | 1.80B |
| Operating income | 471.18M | 610.00M | 241.00M | 540.00M | 330.00M | 400.00M | 154.00M | 199.00M | 337.00M | 816.00M | -824.00M | 24.00M |
| Net income | 26.84M | 384.00M | 151.00M | 395.00M | 184.00M | 240.00M | 76.00M | -335.00M | 181.00M | 451.00M | -999.00M | 39.00M |
Balance Sheet
As of Dec 2025, total debt of EUR 8.09B exceeded cash and equivalents by 5.29B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 26.94B | 28.98B | 29.41B | 30.69B | 30.96B | 27.71B | 27.02B | 26.02B | 25.32B | 32.30B |
| Current assets | 9.93B | 10.02B | 9.94B | 10.26B | 10.35B | 11.23B | 9.46B | 9.57B | 10.12B | 14.07B |
| Cash and equivalents | 2.79B | 2.40B | 1.87B | 1.17B | 2.30B | 3.23B | 1.43B | 1.69B | 1.94B | 2.33B |
| Total liabilities | 15.96B | 16.93B | 17.34B | 17.41B | 16.49B | 15.81B | 14.39B | 13.90B | 13.29B | 18.80B |
| Short-term debt | 1.15B | 443.00M | 334.00M | 325.00M | 310.00M | 1.23B | 382.00M | 1.39B | 672.00M | 1.58B |
| Long-term debt | 6.93B | 6.19B | 6.09B | 7.27B | 6.47B | 5.71B | 3.77B | 3.00B | 3.27B | 4.02B |
| Shareholder equity | 10.96B | 12.01B | 12.03B | 13.25B | 14.44B | 11.87B | 12.60B | 12.09B | 12.00B | 12.60B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 28.50B | 26.70B | 27.29B | 26.94B | 26.34B | 26.38B | 27.17B | 28.98B | 11.92B | 29.47B | N/A | 29.41B |
| Total liabilities | 16.70B | 15.22B | 15.86B | 15.96B | 15.76B | 15.97B | 15.44B | 16.93B | -11.92B | 17.55B | -12.06B | 17.34B |
| Cash and equivalents | 2.80B | 1.79B | 2.59B | 2.79B | 1.91B | 1.82B | 1.19B | 2.40B | 1.81B | 1.81B | -1.87B | 1.87B |
| Shareholder equity | 11.78B | 11.45B | 11.40B | 10.96B | 10.55B | 10.38B | 11.70B | 12.01B | 11.92B | 11.88B | 12.06B | 12.03B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 77.0% of operating cash flow. Dividends came to 36.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.16B | 1.57B | 2.14B | -173.00M | 1.63B | 2.78B | 2.03B | 1.78B | 1.87B | 1.90B |
| Capital expenditures | 269.00M | 676.00M | 554.00M | 806.00M | 763.00M | 942.00M | 1.01B | 843.00M | 859.00M | 869.00M |
| Free cash flow | 893.00M | 893.00M | 1.58B | -979.00M | 866.00M | 1.83B | 1.02B | 937.00M | 1.01B | 1.03B |
| Dividends paid | 328.00M | 1.00M | 2.00M | 412.00M | 482.00M | 1.00M | 453.00M | 401.00M | 384.00M | 330.00M |
| Investing cash flow | -737.00M | -573.00M | -636.00M | -1.49B | -3.67B | -1.32B | -603.00M | -1.49B | -3.20B | -1.17B |
| Financing cash flow | 107.00M | -496.00M | -848.00M | 500.00M | -2.35B | 483.00M | -1.67B | -1.19B | 55.00M | -420.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 543.34M | 376.00M | 191.09M | 1.39B | 327.00M | 387.00M | -981.95M | 1.38B | 274.00M | 89.00M | -171.00M | 1.65B |
| Capital expenditures | 74.58M | 157.00M | 74.20M | 83.00M | 68.00M | 159.00M | 57.89M | 506.00M | 0 | 159.00M | 170.00M | 488.00M |
| Free cash flow | 468.76M | 219.00M | 116.89M | 1.31B | 259.00M | 228.00M | -1.04B | 871.00M | 274.00M | -70.00M | -341.00M | 1.16B |
Frequently Asked Questions About PHG
What is Koninklijke Philips NV ADR's annual revenue?
Koninklijke Philips NV ADR reported revenue of EUR 17.83B for the fiscal year ended Dec 31, 2025.
How fast is Koninklijke Philips NV ADR's revenue growing?
Revenue was down 1.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.0%.
Is Koninklijke Philips NV ADR profitable?
Yes. Koninklijke Philips NV ADR reported net income of EUR 895.00M for the fiscal year ended Dec 31, 2025, with a net margin of 5.0%.
How much free cash flow does PHG generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR 1.16B minus capital expenditures of EUR 269.00M produced free cash flow of EUR 893.00M.
How much debt does Koninklijke Philips NV ADR have?
The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 6.93B, short-term debt of EUR 1.15B and cash and equivalents of EUR 2.79B.
PHG pages: Overview, Dividends, Financials, Valuation, Competitors, Government Contracts